Pre-clinical studies show that tipifarnib has antiproliferative effects on pancreatic cancer cell lines at clinically relevant concentrations (concentration that inhibits 50% growth [IC50] from 9.5 to 500 nmol/L). It also exhibits marked growth retardation and antiangiogenic effects in a pancreatic cancer xenograft model.
Synonyms: (R)-(+)-R 115777; 6-[(R)-Amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone; R115777
Molecular Formula: C27H22Cl2N4O
Molecular Weight: 489.4
Linear Structural Formula: C27H22Cl2N4O
MDL Number: MFCD07772347
Purity: >=98% (HPLC)
Storage: -20C
Biochem Physiol Actions: Tipifarnib (R115777) is an orally active and potent farnesyltransferase (FTase) inhibitor that exhibits potent anti-tumorigenic effects. Tipifarnib mechanism of action is not fully understand.